Estamos no ar no ! Saiba mais
ícone de AMPH

Amphastar Pharmaceuticals

25,87 USD
-0,55
2,08%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
25,80
-0,07
0,27%
1 dia
-2,08%
5 dias
-2,82%
1 mês
8,02%
3 meses
30,26%
6 meses
18,62%
No acumulado do ano
-2,23%
1 ano
11,41%
5 anos
35,94%
10 anos
43,4%
 

Sobre: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

Funcionários: 1.976

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 33,3%
Neutro 41,7%
Negativo 25%
Positivo
Zacks Investment Research
há 10 dias
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Neutro
PRNewsWire
mês passado
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Positivo
Zacks Investment Research
mês passado
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Negativo
Zacks Investment Research
há 2 meses
New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
New Strong Sell Stocks for August 14th
Neutro
Seeking Alpha
há 2 meses
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Positivo
Zacks Investment Research
há 2 meses
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Positivo
Zacks Investment Research
há 2 meses
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Negativo
MarketBeat
há 2 meses
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Neutro
PRNewsWire
há 2 meses
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Negativo
Zacks Investment Research
há 2 meses
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Gráficos de preços implementados com Lightweight Charts™